University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Full Title Metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes.

Herring, Roselle A., Shojaee-Moradie, Fariba, Garesse, Robert, Stevenage, Mary, Jackson, Nicola, Fielding, Barbara, Mendis, Agampodi, Johnsen, Sigurd, Umpleby, Margot, Davies, Melanie and Russell-Jones, David L. (2020) Full Title Metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes Care.

Herring et al Diabetes Care May 2020.pdf - Accepted version Manuscript

Download (474kB) | Preview
Diabetes care_supplement Tables and figures May 2020.pdf - Supplemental Material

Download (182kB) | Preview


Objective: To determine the effect of SGLT2 inhibitor dapagliflozin on glucose flux, lipolysis and ketone body concentrations during insulin withdrawal in people with type 1 diabetes. Research Design and Methods: A double-blind placebo controlled crossover study with a 4-week wash out period was performed in 12 people with type 1 diabetes using insulin pump therapy. Participants received dapagliflozin or placebo in random order for 7 days. Stable isotopes were infused to measure the rate of glucose production (Ra), disappearance (Rd) and lipolysis. At isotopic steady state insulin was withdrawn and the study terminated after 600 minutes or earlier if blood glucose reached 18mmol/L, bicarbonate <15mmol/L, venous pH <7.35 or capillary ketones >5.0 mmol/L. Results: At baseline, glucose Ra was significantly higher with dapagliflozin than placebo. Following insulin withdrawal, plasma glucose concentrations at the end point were significantly lower with dapagliflozin than placebo and AUC0-180min glucose Rd and AUC0-180min β-hydroxybutyrate (BOHB) were significantly higher. There was a small but significantly higher AUC0-180min glycerol Ra (measure of lipolysis) with dapagliflozin. Non-esterified fatty acid concentrations were not different between treatments.When divided by BMI>27 and <27kg/m2, basal glucose Ra and BOHB, and AUC0-180min glycerol Ra were significantly higher in the low BMI group with dapaglifozin versus placebo treatment. Conclusions: During insulin withdrawal the increase in BOHB with 3 dapaglifozin may be partially due to increased lipolysis. However reduced renal excretion, reduced BOHB uptake by peripheral tissues or a metabolic switch to increase ketogenesis within the liver may also play a role.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
Herring, Roselle A.
Shojaee-Moradie, Fariba
Garesse, Robert
Stevenage, Mary
Mendis, Agampodi
Johnsen, Sigurd
Davies, Melanie
Russell-Jones, David L.
Date : 30 May 2020
Funders : Diabetes UK
Depositing User : James Marshall
Date Deposited : 10 Jun 2020 10:41
Last Modified : 10 Jun 2020 10:41

Actions (login required)

View Item View Item


Downloads per month over past year

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800